The utilization of cord blood as a source of stem cells for transplantation has decreased in recent years. Although cord blood transplantation (CBT) is an established practice for the treatment of adult and pediatric patients with hematological malignancies, the high acquisition cost of CB units along with high transplant-related mortality due to delayed hematopoietic recovery and immune reconstitution have contributed to the slowing in widespread adoption of CBT. Strategies aimed to enhance speed of engraftment and ongoing clinical trials are investigating ways to make CBT more widely available. Meanwhile, the recent clinical data suggest that the choice of CBT might be preferable for patients with pre-transplant minimal residual disease. We review here the background data on the utilization of CB for the treatment of hematological malignancies, and discuss the current challenges and future directions in the field of CBT.
INTRODUCTION
In recent years, umbilical donor cord blood transplantation (CBT) has emerged as a feasible alternative source of hematopoietic progenitors for pediatric and adult patients with hematological malignancies lacking a related and an unrelated donor. [1] [2] [3] [4] The increased level of HLA disparity that can be tolerated makes CBT a very attractive alternative source of hematopoietic stem cells. This feature is particularly important for patients from racial and ethnic minorities, 5 as it can be difficult to find an unrelated donor (URD) for such patients. Indeed, in a recent National Marrow Donor program study, while 75% of white European patients were likely to identify an 8/8 HLA-matched URD, only in 20 and 50% of cases a donor was identified in the URD registry for patients of African and Hispanic ancestry origin, respectively. 6 Over the years multiple retrospective studies have demonstrated that CBT can achieve comparable disease-free survival (DFS) to that of adult donor transplants in patients with hematologic malignancies. [7] [8] [9] Furthermore, many studies have confirmed low rates of malignant relapse after CBT compared with URD transplants, suggesting that cord blood (CB) could be the preferred source for patients at high risk of relapse. [7] [8] [9] CBT also has the advantage of lower rates of chronic GvHD when compared with recipients of peripheral blood stem cell transplant, the most common donor source. 10, 11 Historically, however, the increased risk of non-relapse mortality and cost associated with CBT have impacted its widespread adoption. Recognition of the clinical challenges in the CBT field and strategies instituted by experienced transplant centers to reduce early post-transplant morbidity and mortality are necessary to spread the use of CBT to centers with more limited expertise. Herein we review the early days of CBT, current advantages and challenges, and finally promising efforts to mitigate these and further strengthen its role as a highly desired stem cell source in patients undergoing hematopoietic stem cell transplantation (HSCT).
REWIND
The concept of using CB was developed in the late 1970s, but it was the pivotal work of Hal Broxmeyer that moved CB from the laboratory to clinical practice. 12, 13 Since the first human cord blood transplant, performed in 1988, 14 much has been learned in the field of CBT. CB banks have been established worldwide and CB has been used to transplant over 35 000 recipients. However, over the last 3 years its use as a stem cell source has declined mostly for adult patients, with just under 900 total cord blood transplants performed in 2015 (Source: National Marrow Donor Program/Be the Match 2015). The increased utilization of HLA-halfmatched-related donors (Haploidentical transplants) along with the higher acquisition cost of CB units when compared with other stem cell sources are only in part responsible for the decrease in number of CBT. The results of two parallel-phase trials of non-myeloablative double-unit CBT and haploidentical HCT showed that disease-free survival at 1 year was similar between the two different approaches as result of higher transplant-related mortality and lower relapse after CBT when compared with haploidentical transplants recipients. 15 This study has now led to an ongoing phase III randomized study (BMT CTN 1101).
An increase in early transplant-related mortality (TRM) due to delayed hematopoietic recovery and immune reconstitution, and the requirement for specialized, intensive, early post-transplant management have also contributed to the slowing in widespread adoption of CBT. If this risk of early TRM could be mitigated, then the lower rates of relapse and chronic GvHD associated with CBT could make cord blood a highly desirable stem cell source. If we could utilize our understanding of stem cell biology to generate cells capable of shortening time to engraftment and improving early immune reconstitution with the goal of decreasing early, non-relapse mortality associated with CBT, this would help overcome some of the current challenges with CBT. Ideally, such techniques would also decrease the cost associated with CBT by decreasing the high cost associated with longer inpatient stays and significant post-transplant infectious complications as well as the need for multiple cord blood units to improve stem cell dose. 16 
FAST FORWARD
Enhancing CB engraftment and decreasing non-relapse mortality Early TRM in CBT is primarily due to infectious complications presumably related to the relative delay in neutrophil engraftment and early immune reconstitution associated with CBT as compared with other stem cell sources. [1] [2] [3] [4] There is a clear association between stem cell dose and time to neutrophil engraftment, which has been investigated extensively. 8 The pioneering work by the Minnesota group using a double cord blood transplant platform was a fundamental step in establishing the feasibility of increasing stem cell dose without increasing risk of GvHD or affecting the advantageous GVL effect of CBT. 17 Not only did double CBT allow greater accessibility to this stem cell source, it provided a foundation for a number of emerging technologies whose goal is to improve time to hematopoietic and immunologic recovery post CBT.
Despite the advances achieved with increasing cell dose and dCBT, there remained a gap in time to engraftment and early TRM between CB and other donor sources. Multiple groups thus sought to leverage the rapidly advancing field of stem cell biology to manipulate CB hematopoietic stem/progenitor cells (HSPC) toward enhanced engraftment and immune reconstitution potential. These approaches have primarily focused on generating greater numbers of HSPC by stimulating progenitor cell selfrenewal or blocking differentiation into more mature cell types.
To alleviate the risks associated with delayed neutrophil engraftment, our group developed methods to expand CB HSPC based on previously described studies of the role for the Notch receptor family in regulation of hematopoiesis. 18, 19 This led to the development of a preclinical Notch-mediated expansion system for hematopoietic progenitors using the Notch ligand Delta. 20 Clinical translation of this work led to a phase I CBT trial using ex vivo expanded CB progenitors, following myeloablative conditioning and infusion of an unmanipulated cord blood unit.
Results of this initial trial demonstrated the safety of this approach as well as a significant reduction in time to neutrophil recovery. 20 Importantly, these patients did not have increased rates of graft rejection or GvHD as compared with historical controls. While these results were very promising, they relied on real-time expansion of a cord blood unit, which is not feasible on a largescale. Our group has thus transitioned to development of an expanded, cryopreserved product that is infused without HLAmatching following one or two unmanipulated cord blood units. Early studies of this have been quite promising. 21 The results of this Phase II safety study demonstrated that infusion of an off-theshelf non-HLA-matched expanded CB HSPC product to augment a CB graft in the myeloablative setting was safe and led to more rapid neutrophil and platelet recovery compared with our historical control group. Importantly, no TRM was observed among the 15 patients enrolled on this study, leading to an excellent DFS of 86% at a median follow-up of 5 years. No grade 3-4 acute GvHD was observed even with infusion of a non-HLA-matched expanded cell product. This approach is now being investigated in an ongoing randomized Phase II study (NCT01690520).
Others have generated similarly promising technologies to address the concern of early TRM and delayed immune reconstitution post transplant and these have been reviewed extensively. [22] [23] [24] Some of these are in ongoing clinical trials. These include those focused on enhancing homing and survival of infused cord blood progenitors to augment engraftment such as the use of dmPGE 2 to enhance CB homing when CB HSPC are incubated ex vivo pre transplant. 25 Some other current efforts include: inhibition of the enzymatic activities of Dipeptidylpeptidase (DPP)4, 26 short term treatment of cells with hyperthermia, 27 and enforced fucosylation of the cells. 28 Other approaches, similar to ours, have sought to model the ex vivo stem cell niche. A particularly promising approach has been the work by de Lima et al, 29 utilizing mesenchymal stem cells to ex vivo expand CB progenitor cells that are infused in addition to an unmanipulated CB unit. In a Phase I study of 31 adults treated with this approach, de Lima et al improved median time to neutrophil engraftment from 24 days to 15 days. This product was licensed by Mesoblast, Ltd and is now undergoing evaluation in a phase III study. Recent identification of small molecules that enhance expansion of CB progenitor cells ex vivo have also entered clinical trials, including the use of a copper chelator TEPA now licensed as NiCord (Gamida Cell Ltd., Stem Cell Therapy Technologies, Jerusalem, Israel) and an aryl hydrocarbon receptor antagonist SR1. [30] [31] [32] In a phase I trial, 11 adults with hematologic malignancies received myeloablative bone marrow conditioning followed by transplantation with NiCord and a second unmanipulated CB unit. Median time to achieve neutrophil recovery was 13 days in patients transplanted with NiCord with a 1-year overall and PFS rates of 82 and 73%, respectively. 30 All of these technologies require ongoing testing to confirm not only long-term safety but also efficacy at not only blood system reconstitution but also immune reconstitution and ultimately reduction in post-transplant morbidity and mortality. While there is still work to be done, the landscape for enhancing CB transplant is quite promising and has the potential to reduce the non-relapse morbidity and mortality associated with cord blood transplant. Table 1 summarizes the main current and past methodologies that have been explored to reduce time to engraftment. 33 The authors found that among children and adolescents with hematologic malignancies, survival rates were similar after single-unit and double-unit CBT; however, a singleunit cord-blood transplant was associated with better platelet recovery and a lower risk of GvHD. Furthermore, this trial demonstrated a high-rate of overall survival regardless of the number of CBU received. The overall survival rate was 65% among double-unit recipients and 73% among single-unit recipients. Similarly to prior retrospective studies the incidence of relapse was extremely low in both groups: 14% in recipients of a doubleunit transplant and 12% in recipients of a single-unit transplant.
Very recently, we have confirmed that CBT is associated with excellent clinical outcomes in the largest single-center retrospective study ever conducted. 34 We identified 582 patients with acute leukemia or myelodysplastic syndrome who received first myeloablative HSCT using either CB donor (140 patients), an HLAmatched unrelated donor (344 patients), or an HLA-mismatched unrelated donors (98 patients) as the stem cell source. We found that, for patients with minimal residual disease pre-transplant, overall survival was better for those who received CBT than after HLA-mismatched unrelated donor transplants. Moreover, there was a trend toward better overall survival among patients with minimal residual disease who underwent CBT as compared with those who received HLA-matched unrelated donor transplants. Among patients who had minimal residual disease, the risk of death was significantly higher in the HLA-mismatched group than in the cord blood group (hazard ratio (HR), 2.92; P = 0.0001) and trended toward being higher in the HLA-matched group than in the cord blood group (HR, 1.69; P = 0.08). The risk of relapse among these patients also was significantly higher in both unrelated donor groups than in the cord blood group. The HR for relapse in the HLA-matched group versus the CB group was 2.92 (P = 0.007), and the HR in the HLA-mismatched group versus the CB group was 3.01 (P = 0.02). Among patients who did not have minimal residual disease, there were trends toward worse overall survival and relapse rates in the unrelated donor groups versus the CB group, but the differences were not statistically significant.
Taken together, these results establish and reinforce CBT as a standard therapy, especially for patients with high risk hematologic malignancies. The increased level of HLA mismatching could explain the lower risk of relapse observed in CBT when compared with matched and mismatched unrelated transplants. In addition, the potential graft-versus-graft interactions that are unique in the double-CBT setting (90% of patients received a double CBT in our study) could also have had an important role in augmenting the GVL effect, 35 although the results of the randomized pediatric study indicate that double-CBT does not confer a survival advantage in children and adolescents.
FUTURE DIRECTIONS
Much has been learned over the past 30 years about the properties of CB HPSC and their application to stem cell transplantation and to regenerative therapies in neurological diseases, including genetic diseases of childhood, ischemic events such as stroke and neurodegenerative diseases of adulthood. 36 In particular, CBT is now an established therapy for the treatment of hematologic malignancies. Recent trials have further validated the use of CBT showing superb outcomes in both pediatric and adult patients even without the new technologies highlighted above. A better understanding of the unique supportive care requirements for CBT patients as well as improved selection criteria for cell dose and quality of the CBU have led to decreases in NRM and graft failure rates. In addition, CB may be the preferred donor source in certain clinical situations, in particular, as recently demonstrated in patients with evidence of pretransplant minimal residual disease. Similarly, for patients with high risk of relapse, a CB donor may have the advantage of a lower relapse rate, and the ability to rapidly identify and procure stem cells to proceed expeditiously to transplant. CBT offers a unique platform, in which the CB units (donors) are readily available and there is no risk assumed by the donor that is in contrast to stem cell transplants using bone marrow or peripheral blood stem cell sources.
However, several ongoing challenges remain to expand the use of CBT. While many methods to improve the speed of engraftment and decrease TRM have been successfully investigated, very little has been done to improve the cost of CB grafts and supportive care early post transplantation. These two aspects have significantly contributed to the observed decrease in the number of CBT over the past 3 years, resulting in fewer centers with enough experience to adequately perform CBT. New approaches to enhance engraftment with the main goal of reducing TRM have the potential to address these drawbacks and significantly broaden the use of CB as a stem cell source. However, a careful evaluation of these new techniques is necessary both for their long-term safety as well as their economic viability for widespread use. With the development of technologies that would allow for large-scale production of non-HLA matched, off-the-shelf stem cell products capable of improving time to neutrophil engraftment and decreasing transplant-related complications, one could envision progression towards a more cost-effective single-unit cord blood transplant due to less utilization of expensive supportive care measures and inpatient hospital time. Successful reduction of TRM and graft failure coupled with the unique clinical merits of CBT, including its lower rate of relapse would further improve outcomes in CBT patients and have the potential to lead to more widespread adoption of CBT as a stem cell source.
